NEWS
EU expands look at Zhejiang Huahai as impurities show up in other 'sartans'A global recall may get expanded beyond valsartan as regulators continue to find potentially cancer-causing impurities in other “sartan” products.
- India watching China’s measures to ease drug-import norms
In June, pharmaceutical exporters from India had meetings with representatives from the China Food & Drugs Administration (CFDA) on the problems being faced by them in the Chinese market.
- Mid 2018 – Recap of Warning Letters, Import Alerts and Non-Compliances
In our mid-2018 compliance review, we look at inspection challenges faced by companies across the world. In the first half of this year, manufacturing compliance challenges dominated headlines.
- Discovery of kidney cancer driver could lead to new treatment strategy
University of North Carolina Lineberger Comprehensive Cancer Center scientists have uncovered a potential therapeutic target for kidney cancers that have a common genetic change. University of North C
- Li Gang, Chairman of Sihuan Pharmaceutical Co., Ltd. , visits Bangladesh
Li Gang, the chairman of Sihuan Pharmaceutical Co., Ltd. went to Bangladesh to visit the Ministry of Health of Bangladesh (BDH) and the Bangladesh Pharmaceutical Federation (BAPI) and held talks with
- The listing application is approved by CFDA Boehringer Ingelheim blockbuster drug diethylsulfonate nid
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrotic interstitial lung disease. The lesions are confined to the lungs and are more common in the elderly.